[go: up one dir, main page]

DE69726571D1 - Rekombinantes humanes Erythropoietin mit vorteilhaftem Glykosylierungsmuster - Google Patents

Rekombinantes humanes Erythropoietin mit vorteilhaftem Glykosylierungsmuster

Info

Publication number
DE69726571D1
DE69726571D1 DE69726571T DE69726571T DE69726571D1 DE 69726571 D1 DE69726571 D1 DE 69726571D1 DE 69726571 T DE69726571 T DE 69726571T DE 69726571 T DE69726571 T DE 69726571T DE 69726571 D1 DE69726571 D1 DE 69726571D1
Authority
DE
Germany
Prior art keywords
dna sequences
vectors
polypeptides
erythropoietin
aforedescribed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69726571T
Other languages
English (en)
Other versions
DE69726571T2 (de
Inventor
Dr Fibi
Dr Hermentin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Publication of DE69726571D1 publication Critical patent/DE69726571D1/de
Application granted granted Critical
Publication of DE69726571T2 publication Critical patent/DE69726571T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69726571T 1997-09-01 1997-09-01 Rekombinantes humanes Erythropoietin mit vorteilhaftem Glykosylierungsmuster Expired - Lifetime DE69726571T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97115081A EP0902085B1 (de) 1997-09-01 1997-09-01 Rekombinantes humanes Erythropoietin mit vorteilhaftem Glykosylierungsmuster

Publications (2)

Publication Number Publication Date
DE69726571D1 true DE69726571D1 (de) 2004-01-15
DE69726571T2 DE69726571T2 (de) 2004-11-04

Family

ID=8227297

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69726571T Expired - Lifetime DE69726571T2 (de) 1997-09-01 1997-09-01 Rekombinantes humanes Erythropoietin mit vorteilhaftem Glykosylierungsmuster

Country Status (12)

Country Link
US (1) US6673609B1 (de)
EP (2) EP0902085B1 (de)
JP (1) JP4345077B2 (de)
KR (1) KR100563017B1 (de)
AT (1) ATE255634T1 (de)
AU (1) AU743833B2 (de)
CA (1) CA2303476A1 (de)
DE (1) DE69726571T2 (de)
DK (1) DK0902085T3 (de)
ES (1) ES2208798T3 (de)
PT (1) PT902085E (de)
WO (1) WO1999011781A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
KR20010075661A (ko) * 1998-10-23 2001-08-09 스티븐 엠. 오드레 빈혈 예방 및 치료 방법과 이를 위한 조성물
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
CN1367701A (zh) * 1999-05-11 2002-09-04 奥索－麦克尼尔药物公司 红细胞生成素给药的药代动力学和药效模型
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
AU2001274809A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2437333A1 (en) 2001-02-02 2002-08-22 Ortho-Mcneil Pharmaceutical, Inc. Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
EP1461065A1 (de) 2001-11-28 2004-09-29 Ortho-McNeil Pharmaceutical, Inc. Erythropoetin-dosierschema zur behandlung von anämie
EP2990417A1 (de) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin-insulin-fusionsprotein
AU2003218045A1 (en) 2002-03-11 2003-09-29 Ortho Mcneil Pharmaceutical, Inc Methods for shp1 mediated neuroprotection
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP4155385A1 (de) 2005-12-08 2023-03-29 Amgen Inc. Verbesserte herstellung von glykoproteinen unter verwendung von mangan
CN101062407A (zh) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 促红细胞生成素在预防或治疗视网膜损伤中的用途
CN101939443B (zh) 2008-02-08 2014-01-29 Ambrx公司 经修饰瘦素多肽和其用途
WO2010036964A2 (en) 2008-09-26 2010-04-01 Ambrx Inc. Modified animal erythropoietin polypeptides and their uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77081A (en) * 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5641663A (en) * 1985-11-06 1997-06-24 Cangene Corporation Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
DE3923963A1 (de) * 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
JPH03151399A (ja) * 1989-11-07 1991-06-27 Snow Brand Milk Prod Co Ltd 変異ヒトエリスロポエチン
WO1992006116A1 (en) * 1990-09-28 1992-04-16 Ortho Pharmaceutical Corporation Hybrid growth factors
IL110669A (en) * 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US9505465B2 (en) * 2014-12-15 2016-11-29 Fundamental Consulting Services Inc. Apparatus and method for attaching watercraft

Also Published As

Publication number Publication date
EP1007679A1 (de) 2000-06-14
DK0902085T3 (da) 2004-04-05
PT902085E (pt) 2004-02-27
AU743833B2 (en) 2002-02-07
WO1999011781A1 (en) 1999-03-11
CA2303476A1 (en) 1999-03-11
DE69726571T2 (de) 2004-11-04
JP4345077B2 (ja) 2009-10-14
AU9533798A (en) 1999-03-22
KR100563017B1 (ko) 2006-03-22
ATE255634T1 (de) 2003-12-15
KR20010023500A (ko) 2001-03-26
ES2208798T3 (es) 2004-06-16
JP2001514851A (ja) 2001-09-18
EP0902085B1 (de) 2003-12-03
US6673609B1 (en) 2004-01-06
EP0902085A1 (de) 1999-03-17

Similar Documents

Publication Publication Date Title
DE69726571D1 (de) Rekombinantes humanes Erythropoietin mit vorteilhaftem Glykosylierungsmuster
Marder et al. Molecular architecture of the rapidly metabolized 32-kilodalton protein of photosystem II. Indications for COOH-terminal processing of a chloroplast membrane polypeptide.
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
RU95115239A (ru) Аналог эритропоэтина
ATE352626T1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
ATE319818T1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
CY1112655T1 (el) Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις
DE60018171D1 (de) Verwendung von adenovirus e1 protein sequenzen kodierenden, zur herstellung von rekombinanten proteinen in menschlichen zellen.
IS6927A (is) Nýjar sameindir skyldar interferon-beta
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
ATE414775T1 (de) Polypeptide mit prolyldipeptidylaminopeptidase- aktivität und dafür kodierende nukleinsäuren
DE69020335D1 (de) B-ketten-analoge des von blutplättchen abstammenden wachstumsfaktors und verfahren zu deren homogener herstellung.
ATE56728T1 (de) Neue polypeptide mit alpha-amylase-hemmender wirkung, verfahren zu deren herstellung, deren verwendung und pharmazeutische praeparate.
DE68929430D1 (de) Fibronektin bindendes Protein
NO943949D0 (no) DNA som koder for proteinkomplekser med faktor VIII-C-aktivitet, samt fremstilling derav
NZ503235A (en) Amino-terminally truncated RANTES as chemokine antagonists
DE3751893D1 (de) Polypeptid und dessen Herstellung
ATE490324T1 (de) Nukleinsäuren kodierend für polypeptide mit chips aktivität
HRP940432B1 (en) Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin
NO874704D0 (no) Minaktivin fremstilt ved rekombinant dna-teknikk.
ATE317896T1 (de) Polypeptide mit glucanotransferase aktivität und dafür kodierende nukleinsäuren
DE602004019556D1 (de) Neues plexin-polypeptid, dieses codierende dna und verwendung davon

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, 65929 FRANKFURT,